- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 12, 2023
Deals
Sept. 12 Quick Takes: Exelixis takes rights to Insilico’s synthetic lethal molecule
Plus: Vertex, Septerna in GPCR deal and updates from Pierre Fabre, Vertical, Traverse, Genmab, Neurocrine, Rome, CymaBay
BioCentury | Feb 20, 2020
Finance
With $88M series B, Spruce seeks short path to approval in rare endocrine disorder
Four-year-old Spruce chose an investor syndicate with experience in rare diseases and public markets
BioCentury | Mar 3, 2016
Distillery Therapeutics
Therapeutics: Corticotropin-releasing factor receptor 1 (CRHR1; CRFR1)
Items per page:
1 - 10 of 17